Device Trial Radar · NCT04523350
Instylla HES Hypervascular Tumor Pivotal Study
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Mar 5, 2021
Primary completion
May 1, 2024
Study completion Nov 19, 2024
Sponsor
- Lead sponsor
- Instylla, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 21, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an acceptable risk of device and procedure-related serious adverse events.
Conditions
- Hypervascular Tumors
Interventions
Instylla HESDevice
Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)
TAE or cTACEOther
Bland TAE or cTACE
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness Endpoint: Delivery of the Embolic Agent to the Index Tumor Feeding Vessel With Stasis of Flow as Determined by an Independent Radiologist Via Comparison of the Pre and Final Post Procedure ImagesTime frame: Immediately post-embolization procedure
- Primary Safety Endpoint: Freedom From Major Adverse Events Through 30 Days Post-index ProcedureTime frame: 30 days post-embolization procedure
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
UAB Hospital
Birmingham, Alabama
Central Arkansas Radiation Therapy Institute, Inc.
Little Rock, Arkansas
University of California, Irvine
Irvine, California
12 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.